ミトコンドリアの電子の流れを操作すると,腫瘍の免疫性が増大する

Kailash Chandra Mangalhara¹, Siva Karthik Varanasi¹, Melissa A Johnson¹

¹Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Science (New York, N.Y.)

|September 21, 2023

まとめ

複合体Iではなくミトコンドリア複合体IIの喪失は,T細胞の反応を高めることでメラノーマの成長を遅らせます. 電子伝送鎖の再配線は癌治療の戦略となる可能性があります

科学分野:

癌生物学
免疫学
ミトコンドリア代謝

背景:

腫瘍の成長はミトコンドリア電子輸送鎖 (ETC) に依存する.
腫瘍進行におけるETC複合体I (CI) と複合体II (CII) の異なる役割は完全に理解されていません.
これらの役割を理解することは新しいがん治療法の開発に不可欠です

研究の目的:

メラノーマ腫瘍の成長におけるCIとCIIの違いを調査する.
免疫反応と腫瘍制御に対する ETC 調節の影響を調査する.
癌治療におけるETC成分を標的とした治療の可能性を評価する.

主な方法:

CIとCIIの遺伝子ノックアウトでメラノーマの細胞モデルを使用した.
腫瘍の成長率と免疫細胞の浸透を分析した
抗原表現に関連する遺伝子発現と表遺伝的変異を調査した.
遺伝子操作 (MCJのノックアウト) を使って ETCの電子入りを再接続した.

主要な成果:

CIIの減少はメラノーマの増殖を著しく減少させた.
CII欠乏症は抗原の呈現を高め,T細胞による腫瘍破壊を促した.
サクシネート蓄積は主要な組織相容性複合体-抗原処理および表示 (MHC-APP) 遺伝子を活性化しました.
MCJノックアウトは,抗腫瘍免疫を促進するためのETC再配線の戦略を示しました.

結論:

CIIはメラノーマ腫瘍の成長を支援する上で重要な役割を果たします.
CIIを標的にしたり,ETC経路を調節したりすると,抗腫瘍免疫反応が強化されます.
ETC再配線は抗原表現が低下した癌の治療に有望な選択肢です

さらに関連する動画

07:57

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry

Published on: December 26, 2019

12.2K

11:32

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates

Published on: August 6, 2021

2.7K

関連する概念動画

01:46

Electron Transport Chain: Complex I and II

14.3K

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

14.3K

02:53

Adaptive Mechanisms in Cancer Cells

5.8K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

5.8K

01:27

Tumor Immunotherapy

551

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

551

02:17

The Tumor Microenvironment

6.7K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

6.7K

01:37

Energy to Drive Translocation

2.1K

Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...